Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD01 in Gynecologic Malignancies
NCT06552598Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KD01 in gynecologic malignancies, Cervical Cancer (CC) and endometrial cancer (EC), sponsored by Tongji Hospital. Primary endpoints: Serious Adverse Events and Adverse Events at 2 years, Maximum Tolerated Dose and Recommended Dose at 2 years and 2 more. Started Apr 2024; status: recruiting.
02
Drugs
KD01
03
Conditions
gynecologic malignanciesCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06552598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552598.